Corcept (CORT) Officer Reports 200-Share Donation; Holdings Now 5,287

Rhea-AI Filing Summary

William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported a transaction dated 09/19/2025. The Form 4 shows a disposition of 200 shares of Common Stock coded as G(1) at a price of $0, with an explanatory note that the shares were donated to a Fidelity Charitable Giving Account. Following the reported transaction, the reporting person beneficially owned 5,287 shares. The form is signed by an attorney-in-fact and cites a power of attorney on file with the SEC.

Positive

• Transparent disclosure of the transaction including date, amount disposed, and post-transaction holdings
• Explanation provided that the disposition was a donation to a Fidelity Charitable Giving Account
• Form signed and power of attorney referenced, indicating procedural completeness

Negative

• Reduction in insider holdings of 200 shares (beneficial ownership falls to 5,287 shares)
• No percentage of outstanding shares disclosed, so ownership stake relative to total shares outstanding is not shown

Insights

Financial Analyst

TL;DR: Insider reported a 200-share donation, reducing beneficial holdings to 5,287 shares; transaction appears non-sale and non-cash.

The Form 4 discloses a non-cash disposition coded G(1) that the filer explains as a donation to a charitable account. Because the transaction is a gift, no cash proceeds are reported and the entry lists a price of $0. The remaining beneficial ownership is explicitly stated as 5,287 shares. The filing provides straightforward disclosure of the change in ownership but contains no financial details about total insider stake percentage or company-wide share counts, so materiality to the cap table cannot be assessed from this form alone.

Corporate Governance Expert

TL;DR: Proper Section 16 disclosure of a charitable disposition; documentation and signature by attorney-in-fact noted.

The report uses the G(1) transaction code and includes an explicit explanation identifying the recipient as a Fidelity Charitable Giving Account, which aligns with Rule 16 reporting for gifts. The filing notes that a power of attorney was used and is on file with the Commission, and it is signed by the attorney-in-fact. The form meets standard disclosure elements: reporting person identity, relationship to issuer, transaction date, amount disposed, post-transaction holdings, and explanation. No governance concerns or corrective amendments are indicated within this document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		G(1)		200	D	$0	5,287	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a donation by the Reporting Person to Fidelity Charitable Giving Account.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did William Guyer report on Form 4 for CORT?

The Form 4 reports a disposition of 200 shares of Corcept Therapeutics common stock dated 09/19/2025, coded as a donation (G(1)).

Was the disposition a sale or a donation?

The filing explains the transaction as a donation to a Fidelity Charitable Giving Account and shows a price of $0.

How many shares does the reporting person own after the transaction?

Following the reported transaction, the reporting person beneficially owned 5,287 shares.

Who signed the Form 4?

The Form 4 was signed by Joseph Douglas Lyon as attorney-in-fact for William Guyer; the form notes a power of attorney is on file with the SEC.

What is the reporting person's role at Corcept Therapeutics?

The reporting person is listed as an Officer with the title Chief Development Officer.